(NASDAQ: KRYS) Krystal Biotech's forecast annual revenue growth rate of 56.29% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.38%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.84%.
Krystal Biotech's revenue in 2024 is $166,233,000.On average, 4 Wall Street analysts forecast KRYS's revenue for 2024 to be $8,414,140,457, with the lowest KRYS revenue forecast at $7,691,007,615, and the highest KRYS revenue forecast at $9,049,934,250. On average, 4 Wall Street analysts forecast KRYS's revenue for 2025 to be $14,625,411,997, with the lowest KRYS revenue forecast at $13,336,442,790, and the highest KRYS revenue forecast at $16,890,337,605.
In 2026, KRYS is forecast to generate $17,539,433,365 in revenue, with the lowest revenue forecast at $15,892,833,741 and the highest revenue forecast at $20,110,965,000.